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Chimeric monoclonal antibody G250 (WX-G250) binds to a cell surface antigen found on 490% of renal cell carcinoma (RCC). A
multicentre phase II study was performed to evaluate the safety and efficacy of WX-G250 in metastatic RCC (mRCC) patients. In all,
36 patients with mRCC were included. WX-G250 was given weekly by intravenous infusion for 12 weeks. Patients with stable
disease (SD) or response were eligible to receive additional treatment for 8 weeks. None of the 36 enrolled patients experienced
any drug-related grade III or IV toxicity. Only three patients had grade II toxicity possibly related to the study medication. In all, 10
patients had SD and received extended treatment. One complete response and a significant regression was observed during the
follow-up of the treatment. Five patients with progressive disease at study entry were stable for more than 6 months after study
entry. The median survival after treatment start was 15 months. The weekly schedule of WX-G250 was well tolerated. With a
median survival of 15 months after the start of this treatment and two late clinical responses, WX-G250 seems to be able to
modulate mRCC. To improve the activity of WX-G250-specific antibody-dependent cellular cytotoxicity and the clinical response
rate, currently combinations of WX-G250 with cytokines are in phase II trials.
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Patients with metastasised renal cell carcinoma (mRCC) have a
poor prognosis. Up to one-third of the newly diagnosed patients
present with metastatic disease and another 33% of the patients
develop recurrent disease after surgery with curative intent
(Mulders et al, 1997). In view of well-documented spontaneous
remissions, the immune system appears to play a role in the
natural history of the disease (Gleave et al, 1998). Against this
background, the main focus of the treatment of mRCC has been on
immunotherapy. Currently, interferon-a (IFN-a) and interleukin-2
(IL-2) are most commonly used in the treatment of mRCC, either
alone or in combination (Negrier et al, 1998; Medical Research
Counsil, 1999). However, the response rates are low and the
toxicity significant. Therefore, new treatment modalities are
being studied (Nathan and Eisen, 2002; Oosterwijk-Wakka et al,
2002).
Currently, several monoclonal antibodies (mAbs) have been
approved for the use of cancer treatment, for example, in non-
Hodgkin’s lymphoma (McLaughlin et al, 1998). In RCC, the
chimeric monoclonal antibody WX-G250 has been identified and
developed for both diagnostic and therapeutic purposes (Ooster-
wijk et al, 1986; Steffens et al, 1997). It recognises the CA-IX
MN/G250
antigen expressed in 495% of RCC of the clear cell type
(Grabmaier et al, 2000). Moreover, CA-IX
MN/G250 is not expressed
in normal kidney tissue and in other normal tissues, the expression
is highly restricted and limited to large bile ducts and gastric
epithelium (Oosterwijk et al, 1986). The observation that WX-G250
was able to mediate antibody-dependent cellular cytotoxicity
(ADCC) against several RCC cell lines (Surfus et al, 1996) led to
the initiation of the present study.
PATIENTS AND METHODS
Study design
A phase II, prospective, open-label, single-arm, multicentre study
was initiated. Patients with mRCC received weekly doses of 50mg
WX-G250 for 12 weeks. Study objectives included the evaluation of
efficacy, safety, immunogenicity and biological activity of the WX-
G250. Patients were treated at five medical centres: Johannes-
Gutenberg University Hospital Mainz, Germany (enrolled patients:
n¼14); Hospital Northwest Frankfurt/Main, Germany (n¼11);
University Medical Center Nijmegen, The Netherlands (n¼6);
Philipps University Hospital, Marburg, Germany (n¼4); and
Daniel den Hoed Cancer Center, Erasmus MC, Rotterdam, The
Netherlands (n¼1). All patients signed an informed consent
approved by the local ethical committees of the respective
hospitals. Patients were recruited between 14 June 2000 and 20
December 2000.
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lPatient population
All patients had primary RCC of clear cell histology and prior
nephrectomy. The inclusion criteria were: bidimensionally mea-
surable disease with lesions o5cm in diameter and at least one
lesion of X1cm; life expectancy 428 weeks; Karnofsky perfor-
mance status X70%; seronegative for human immunodeficiency
virus and hepatitis B surface antigen; absolute neutrophil count
X2.0 10
8/dl; platelet count X100 10
8/dl; haemoglobin
46.5mmol/l (equals 10.5g/dl); total bilirubin o1.5 upper limit
of normal (ULN); AST, ALT o3 ULN (o5 ULN if liver
metastases is present). Patients with clinical signs of CNS
metastases and patients with bone metastases only were excluded.
Antibody
WX-G250 is a human/mouse chimeric mAb (IgG1 isotype) derived
from murine mAb G250 by recombinant DNA techniques. WX-
G250 is similar with regard to binding affinity and specificity in
comparison with the murine G250 IgG (Steffens et al, 1997). All
clinical lots were generated starting from a cell bank according to
current GMP requirements. The antibody was supplied by Wilex
AG (Mu ¨nchen, Germany).
Treatment
Patients received 50mg WX-G250 once a week by intravenous
infusion for 12 weeks followed by radiographic evaluation 4 weeks
later. Patients with stable disease (SD) or a tumour response were
eligible for extended treatment, consisting of eight additional
weekly infusions of WX-G250. The WX-G250 was dissolved in
10ml solution for injection, prefiltered through a low-protein
binding 0.2mm filter and infused in 50–100ml normal saline over
a period of 30min. Patients were observed for at least 2h for blood
pressure, pulse, temperature and allergic reactions after comple-
tion of the infusion. The 50mg dose was chosen based on the
following observations: (1) a single dose of 50mg WX-G250
(radiolabelled with
131Iodine) was safe in 16 RCC patients (Steffens
et al, 1997); (2) 50mg WX-G250 was sufficient to reach maximum
uptake of the antibody in RCC (Steffens et al, 1997); and (3) the
results of a multidose phase I study with escalating WX-G250
doses showed that weekly doses of 25mg/m
2 (corresponding to the
50mg dose used in this study) caused no clinical or laboratory
drug-related adverse events during 6 weeks treatment (Wiseman
et al, 2001). The interval of the application was selected based on
the WX-G250 serum half-life of approximately 70h (Steffens et al,
1997). Therefore, it was expected that the levels of WX-G250
adequate to induce ADCC would persist for at least 1 week (Surfus
et al, 1996). Weekly administration was not expected to lead to
significant cumulative increase of serum levels of WX-G250.
Human anti-chimeric antibody (HACA) evaluation
A sandwich-type ELISA was used to analyse HACA levels in the
serum of patients as described previously (Steffens et al, 1997). In
brief, unconjugated WX-G250 was coated onto ELISA plates,
followed by incubation with the serum of the patient. The
detection of anti-WX-G250 HACA was performed using biotiny-
lated WX-G250, and a streptavidin-biotinylated peroxidase com-
plex. In 22 patients, pretreatment HACA levels were determined.
Blood samples for HACA evaluation were taken before each
infusion with WX-G250 and regularly during follow-up. The serum
of a patient with positive HACA levels obtained from an unrelated
WX-G250 trial was used as positive control. The calibration curve
for the quantification of anti-WX-G250 HACA was generated using
the WX-G250 anti-idiotypic antibody NUH82 (Uemura et al, 1994).
The limit of detection (LOD) of this ELISA was 8.3ng/ml (NUH82);
the limit of quantification (LOQ) was 27ngml
 1.
Biological activity, ADCC
At baseline and prior to WX-G250 infusion at weeks 4 and 12,
venous blood samples were collected in four sodium heparin
vacutainert CPTt tubes (Becton, Dickinson and Company,
The Netherlands). The tubes were centrifuged (1500g, 30min)
at the treatment site and shipped overnight to the evaluator.
Peripheral blood mononuclear cells (PBMCs) were collected
and frozen in 50% FCS/10% DMSO medium and stored at
 1701C until the time of evaluation. To confirm the presence
and proportion of natural killer (NK) lymphocytes, immunophe-
notyping was performed. The biological activity of WX-G250
was analysed by 4-h
51chromium release assays at different effector
to target cell ratios using autologous cryopreserved PBMC as
effector cells. Target cells were SKRC-17pMW1-c14 (CA-IX
MN/G250
antigen-transfected RCC cell line) and SKRC-17 (CA-IX
MN/G250
antigen-negative RCC cell line). As controls for lytic activity
of the PBMC, P815 cells were used as target cells in the presence
of anti-P815 rabbit antiserum (‘classic’-ADCC). To evaluate the
nonspecific cellular lytic activity, K562 and Daudi cells were
used as additional target cells, in the absence of WX-G250
antibody. The cytolytic activities were expressed as percentage
weighted mean of specific cytolysis (Lamers et al, 1991). Antibody-
dependent cellular cytotoxicity measured against the target cells
incubated with the WX-G250 antibody (1mgml
 1) was corrected
for the ADCC seen against the target cells incubated without the
WX-G250 antibody.
Patient monitoring and efficacy evaluation
Patients were monitored for safety, biological activity of WX-G250,
HACA development and clinical antitumour effects. At baseline
and weeks 4, 12 and 16 medical histories, physical examinations,
urinalysis and laboratory studies including complete blood count
and chemistry panel were performed. Toxicity was evaluated
according to the Common Toxicity Criteria (Version 2.0, April
1999, National Cancer Institute). Computed tomography (CT)
scans of the thorax and abdomen were performed at baseline, at
week 16 and 4 weeks after the extended treatment, when
applicable. Tumour responses were evaluated according to the
following WHO criteria: (1) Complete response (CR): the
disappearance of all known disease determined by two evaluations
not less than 4 weeks apart. (2) Partial response (PR): X50%
decrease in the sum of products of largest and perpendicular
diameters of the lesions that have been measured to determine the
effect of therapy by two evaluations not less than 4 weeks apart, in
the absence of new lesions or progression of any lesion. (3) SD: the
total tumour size has less than 50% and the increase is less than
25% in the size of one or more measurable lesions. (4) Progressing
disease (PD): a 25% or more increase in the size of one or more
measurable lesions, or the appearance of new lesions. For the CT
and MRI evaluations an independent central review was performed
as requested by protocol.
Statistical methods
The study had a two-stage design. In the first stage, 32 evaluable
patients with mRCC were included. In all, 22 additional patients
were allowed to participate (54 patients in total) if at least three
objective responses were observed at the time of the radiological
evaluation at week 16. The study had to be terminated if less than
three patients or more than five had an objective response. At the
maximum enrolment number of 54 patients, the trial was powered
at 80% and based on ap0.05 to detect a difference between an
assumed spontaneous response rate of 5% and an underlying true
response rate of 15%.
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lRESULTS
Patient characteristics (Table 1)
From June 2000 to December 2000, a total of 36 RCC patients were
included. The study population (mean age 64 years, range: 42–77
years, 12 females and 24 male) displayed a total of 107 target
lesions in different sites at study entry. In 29 patients (80.5%),
disease progression was documented before study entry, for four
patients the status was not rated, the remaining three were not
progressive. Of the 36 evaluated patients, 20 patients received prior
systemic treatment that resulted in one CR, one PR, three SD. In
all, 15 patients did not respond to cytokine treatment.
Safety evaluation (Table 2)
All 36 patients received at least one dose of WX-G250 and were
assessed for safety. No dose reduction was necessary. Of the
recruited 36 patients, 30 experienced a total of 160 adverse events
during the course of the study. All grade 3 and 4 toxicities were
considered not to be related to the study medication. An overview
of the observed toxicities is given in Table 2. The grade 4 toxicities
consisted of dyspnoea and pulmonary insufficiency (patient 4),
dyspnoea at rest (3), respiratory insufficiency (5) and gastro-
intestinal bleeding (13). Two patients (4,5) died during the study
(defined as death within 30 days after the last application of study
medication), both due to progression of their disease. None of the
Table 1 Characteristics of the evaluated patients
Pt.
no. Sex
Age
(years)
Prior tumour
therapy
(best response)
Karnofski
(%)
Clinical
status
at start Metastasis
Number of
infusions
Response
after
first cycle
Survival
(months; until
January 2002)
1 M 68 IFN+Vinbl (PD) 90–100 PD Adrenal 12 PD 6
2 F 45 IFN+Vinbl (PD) 70 PD Lung and liver 4 PD 2
3 F 75 None 80 PD Lung 12 PD 4
4 M 51 None 80 PD Lung, liver and LN 11 PD 3
5 F 77 None 90 PD Lung 5 PD 2
6
a M 66 IFN+Vinbl (SD) 80 PD Lung and liver 20 SD 18+
IFN+Vinbl (PD)
5FU+CF (PD)
7 F 58 Radiation (PD) 90–100 PD Lung 12 PD 18+
8 M 77 IFN+Vinbl 80 PD Lung and bone 4 PD Date unknown
5FU+CF
9
a M 68 IFN+Vinbl (SD) 90–100 PD Lung, pleura, adrenal 20 SD 18+
5FU+CF (SD)
10 M 69 IL-2/IFN/5FU (SD) 90–100 PD Lung and liver 12 PD 18+
IL-2/IFN/5FU red (PD)
11 M 66 None 90–100 PD Lung and LN 12 PD 17
12 F 67 None 90–100 UN Liver, spleen and LN 12 PD 18+
13 F 64 IFN+Vinbl (PD) 90–100 PD Lung and liver 11 PD 4
14 M 72 None 90–100 PD Lung 7 PD 1
15 M 51 IFN+Vinbl (PD) 90–100 PD Lung, LN, pancreas 12 PD 17+
16 M 54 IFN+Vinbl (PD) 90–100 PD LN, contralateral kidney and psoas
muscle
12 SD 17+
IFN+cis-RA (PD)
5FU+CF (PD)
17 M 67 IFN+Vinbl 80 PD Lung 5 PD 7
18 M 50 IFN (PD) 90–100 PD Lung 12 PD 9
19 M 43 None 90–100 PD Lung and LN 12 PD 8
20 F 60 None 80 UN LN 12 PD 11
21
a M 69 None 90–100 UN Lung and LN 20 SD 16+
22
a M 70 None 90–100 UN LN 20 SD 13
23
a M 61 None 80 PD Lung, LN and Liver 20 SD 16+
24
a M 56 IL-2 (SD) 90–100 PD LN 20 SD 15+
DC vaccination (SD)
25
a F 52 IFN+cis-RA (CR) 90–100 PD Other kidney 20 SD 15+
26 M 69 IL-2/IFN/5FU (PD) 80 PD Lung and LN 12 PD 15+
27
a M 57 IL-2/IFN/5FU (PR) 90–100 UN Lung 20 SD 15+
28
a F 76 None 90–100 PD Lung and adrenal 20 SD 14
29 M 66 IL-2/IFN/5FU (SD) 80 PD Lung and LN 12 PD 15+
IL-2 inhalation (PD)
30 F 65 IL-2/IFN/5FU (PD) 90–100 PD Lung and LN 12 PD 14+
Toremifene+Vinbl (PD)
31 F 70 IFN+Vinbl (PR) 90–100 PD Lung 12 PD 14+
IFN+Vinbl (PD)
IFN+Vinbl (PD)
32 M 76 None 90–100 PD Lung 12 PD 14+
33 M 71 None 80 PD LN and pleura 12 PD 14+
34 M 57 Vaccination (PD) 90–100 PD Lung 12 PD 7
35 M 67 IFN+cis-RA (SD) 90–100 PD Lung and LN 10 PD 5
36
a F 73 None 80 PD Lung 20 SD 13+
aPatients who received extended treatment. Sex:M¼male, F¼female; response:P D¼progressive disease, SD¼stable disease, PR¼partial response, CR¼complete response,
UN¼unknown; metastasis:L N ¼lymphnode; prior treatment: IFN¼interferon-alpha, Vinbl¼vinblastine, 5FU¼5-fluorouracil, CF¼calcium folinate, IL-2¼interleukin-2, cis-
RA¼cis-retinoic acid, DC¼dendritic cell.
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medication, but due to underlying disease.
Evaluation of HACA
In the evaluated pretreatment sera of 22 patients, no HACA levels
were detected. In three samples of two patients (18,27) levels
higher than the LOD could reproducibly be detected. Serum of
patient 18 showed an equivalent of 76ngml
 1 anti-G250 antibody
NUH82 at treatment week 12. In the sera of patient 27, an
equivalent of 49ngml
 1 anti-G250 antibody NUH82 at extension
week 1 and a value between the LOD and LOQ at extension week 8
could be detected.
Immunological monitoring (Table 3)
In 18 patients phenotypic analysis of PBMC was performed
(Table 3). Consecutive samples of every patient were tested
simultaneously to exclude assay-to-assay variation. In 15 of these
18 patients, the percentage of NK cells was 42% of leucocytes in at
least one of the samples (range: 1–14%). The percentage NK cells
in individual patients remained rather constant during treatment.
Consecutive samples of 21 patients were tested for ADCC capacity
(Table 3). Nine out of 21 patients showed moderate (5–25%) to
high (425%) levels of WX-G250-ADCC activity. Five out of 21
patients showed low levels of WX-G250-ADCC and seven out of 21
patients showed no WX-G250-ADCC activity. Of the 21 patients, 19
tested showed normal levels of ‘classic’-ADCC activity. In general,
WX-G250-related ADCC remained unchanged during the treat-
ment.
Clinical response (Table 1)
Clinical progression before week 16 was seen in eight patients. In
four of these patients progression occurred within 6 weeks after
study entry and further patients were recruited as replacements, in
accordance with the protocol. Patient 16 was judged as SD
according to an outside radiologist, but was subsequently lost to
follow-up. Independent central tumour assessment was performed
at week 16 in the remaining 27 patients. Radiographically proven
progression of the disease was observed in 17 patients, who
therefore did not qualify for extended treatment with WX-G250. Of
these, 10 patients showed SD after 12 weeks of treatment and
continued treatment consisting of eight additional weekly infu-
sions of WX-G250. The clinical status of these patients was
assessed in week 24 and eight out of 10 patients still showed SD.
After completion of the treatment patients were routinely followed
at 3 monthly intervals. The follow-up evaluation revealed a minor
response in patient 9 in week 44 and a CR in patient 21 in week 38.
The evaluation of survival showed a median time to death of 15
months after the start of the WX-G250 treatment. The evaluation
of the first stage of the study did not show three objective
responses at the time of radiological evaluation at week 16.
Consequently, the study did not enter the second stage of the trial.
DISCUSSION
We performed a phase II, prospective, open-label, single-arm,
multicentre study in patients with advanced RCC receiving weekly
doses of 50mg WX-G250 for 12 weeks to evaluate the potential
therapeutic effect of WX-G250. WX-G250 recognises the antigen
CA-IX
MN/G250 that is homogeneously expressed in virtually all clear
cell RCC. More importantly, the expression in normal tissue is
extremely limited, making this antigen an attractive target for
immunotherapy.
During the trial no serious drug-related clinical or laboratory
adverse events were observed, and no dose adjustment was
necessary. Therefore, the toxicity profile of WX-G250 is favourable
and comparable with prior studies evaluating WX-G250 (Steffens
et al, 1997). WX-G250 is a murine-human chimeric antibody, and
may consequently induce the development of HACA. In the
current trial, low levels of HACA were detected in only two out of
35 patients (eight and 27). The HACA levels were not associated
with clinical symptoms, which is in accordance with earlier studies
evaluating WX-G250 (Steffens et al, 1997). This study demon-
strates that multiple infusions with WX-G250 are well tolerated
and can be given safely.
The evaluation of the first stage of the trial showed less than
three objective responses needed to continue into the second stage
of the trial and thus the trial was terminated. Nevertheless, the
follow-up revealed two objective responses: patient 9 presented at
study entry with multiple progressive metastases. After both the
first course and extended treatment, the lesions were rated as
stable. In the following months, radiological evaluation showed a
decrease of the target lesions. Taking all measurable lesions into
account, the response remained slightly below the 50% decrease
required for a partial remission, making it a minor response.
Patient 21 started treatment with WX-G250 immediately after
nephrectomy. At study entry he presented with lymph node
Table 2 Adverse events registered during the study, stratified by NCI class and grade
NCI class Events (N) Pts (N) Pts (%) n.a. Gr I Gr II Gr III Gr IV
Pain 32 15 41.7 0 12 13 7 0
Gastrointestinal 26 14 38.9 0 14 12 0 0
Pulmonary 20 9 25.0 0 5 5 6 4
Cardiovascular (general) 17 12 33.3 0 8 4 5 0
Constitutional symptoms 15 9 25.0 0 10 4 1 0
Neurology 11 8 22.2 0 3 6 2 0
Blood/bone marrow 10 5 13.9 0 1 5 4 0
Not to classify 7 5 13.9 4 3 0 0 0
Renal/genitourinary 5 4 11.1 0 2 1 2 0
Haemorrhage 5 3 8.3 0 3 0 1 1
Hepatic 4 2 5.6 0 0 0 4 0
Infection/febrile neutropenia 3 3 8.3 1 1 1 0 0
Metabolic/laboratory 3 3 8.3 0 1 1 1 0
Allergy/immunology 1 1 2.8 0 0 1 0 0
Ocular/visual 1 1 2.8 0 0 1 0 0
Total 160 30 83.3 5 63 54 33 5
Pts¼patients; Gr¼grade; n.a.¼grade not specified.
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decreased 29% between weeks 16 and 24, and was therefore rated
as SD. In week 38 after study start, a complete remission of all the
lesions was documented. Since spontaneous remissions of RCC
metastases after the removal of the primary tumour do occur
(Gleave et al, 1998), we cannot exclude that the clinical observation
of patient 21 was a reflection of the natural history of the disease,
unrelated to WX-G250.
In all, 11 patients were rated with SD at the radiological
evaluation at week 16. Of those patients, eight showed PD at study
entry, of which two patients (6,23) with previously progressive
liver lesions and others after progression under previous
immunotherapy regimens. These are events that rarely occur,
even after ‘standard’ cytokine treatment (Lissoni et al, 1994;
Escudier et al, 1999; Motzer et al, 2002). Collectively, these results
suggest that WX-G250 has the capacity of modulating the natural
history of metastasised RCC with a safe toxicity profile.
Antibody-dependent cellular cytotoxicity is suggested to be the
main effector mechanism of WX-G250 (Surfus et al, 1996) and is
mediated by the interaction between the Fc region of an antibody
bound to a tumour cell and the Fcg receptors on immune effector
cells, such as neutrophils, macrophages and NK cells (Clynes et al,
2000). In our trial, the levels of WX-G250-mediated ADCC differed
between the patients: 42% of the patients showed moderate ADCC,
whereas 33% showed no ADCC at all. There was no clear
correlation between the proportion of NK cells and the level of
WX-G250-mediated ADCC and no correlation between the in vitro
levels cytotoxicity and the clinical responses. This high variability
in observed ADCC capacity and number of NK cells was also found
in healthy donors (personal observations), suggesting that the
observed variation was not the result of the disease status of the
patients. Molecular studies have shown significant polymorphism
in the genes for the different Fc receptors (Vance et al, 1993).
These polymorphisms may have important functional conse-
quences. The pattern of Fcg RIIIA expression polymorphism is
probably correlated with the ability of NK cells to perform ADCC.
This may be the reason that no correlation between the proportion
of NK cells and the level of WX-G250-mediated ADCC was
observed.
In summary, the weekly schedule of intravenous WX-G250 in
patients with mRCC was safe and well tolerated. The evaluation of
the immunogenicity of WX-G250 demonstrated that an increased
level of HACA does not lead to clinical symptoms. In our trial, one
complete responder, one minor response and a substantial number
of durable disease stabilisations were observed with WX-G250
monotherapy. The median survival after study entry was 15
months. This suggests the capacity of WX-G250 to modulate the
natural history of metastatic RCC. Recently, it was shown that a
variety of cytokines, for example, IL-2 and IFNg, led to the
upregulation of WX-G250-mediated ADCC (Liu et al, 2002).
Subsequently, phase II trials optimising treatment schedules with
WX-G250 by combination with cytokines have been initiated.
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